To include your compound in the COVID-19 Resource Center, submit it here.

No breakthrough therapy designation for Spectrum's poziotinib

Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) lost $4.05 (39%) to $6.39 on Dec. 20 after announcing after market close on Dec. 19

Read the full 207 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE